HCRN GI16-288

Hoosier Cancer Research Network (HCRN) is an independent non-profit clinical research organization that facilitates multi-center oncology trials across the United States. Founded in 1984 as the Hoosier Oncology Group, the organization bridges the gap between academic investigators and the pharmaceutical industry to conduct innovative clinical studies. HCRN provides comprehensive trial management services, including protocol development, data management, and regulatory support. The identifier GI16-288 refers to a specific Phase 2 clinical trial managed by HCRN evaluating the combination of pembrolizumab and capecitabine. This study specifically targets patients with metastatic pancreatic adenocarcinoma to evaluate improved treatment outcomes through combined immunotherapy and chemotherapy.